David Bumcrot, Ph.D.

Scientific Fellow at CAMP4 Therapeutics

Speaker

Prior to joining CAMP4, Dr. Bumcrot led groups at innovative biotech companies advancing novel technologies towards clinical development. He was one of the first employees at Alnylam pharmaceuticals where he spent ten years working to make RNA interference-based drugs a reality for multiple indications, including key contributions to a first-in-class systemically administered siRNA therapeutic tested in an oncology clinical trial. Dr. Bumcrot then moved on to Editas Medicine where his team established the company’s initial therapeutic programs utilizing groundbreaking CRISPR technology.